Alteogen, "We Want to Discuss Possibilities Rather Than Limits" Stock Price 256,500 KRW (6.12%)

Alteogen is trading at 256,500 KRW as of 10:33 AM on the 1st, up 6.12% from the previous day. The trading volume is 325,693 shares, which is 85.52% of the previous day's volume. Alteogen is known as a biosimilar developer.

On May 28, Lee Dong-geon, a researcher at Shinhan Financial Investment, stated, "The value of subcutaneous injection formulation drugs is highlighted along with the scalability of the Hybrozyme contract. The companies possessing related platform technology are only Alteogen and Halozyme. In particular, Alteogen, which grants non-exclusive rights, has limitless scalability compared to Halozyme, which grants exclusive rights. Attention should also be paid to the possibility of additional contracts with the same company. If a contract is signed with Keytruda, which has obtained approval for multiple indications, it is possible to have multiple contracts with the same company rather than a one-time deal." He set Alteogen's target price at 260,000 KRW.

Over the past five days, individual investors have net purchased 46,029 shares of Alteogen, while foreigners and institutions have net purchased 11,715 shares and net sold 54,574 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.